Comparative evaluation of the carcinogenic effect of second and third generation combined oral contraceptives in Drosophila melanogaster
DOI:
https://doi.org/10.33448/rsd-v13i1.43352Keywords:
Combined oral contraceptives; Drosophila melanogaster; Carcinogenesis; Neoplasms.Abstract
Objectives: The objective of this work is to comparatively evaluate the carcinogenic effect of contraceptives combined with the progestins levonorgestrel (second generation) and desogestrel (third generation), through the test for detection of epithelial tumors in Drosophila melanogaster. Methods: To this end, three concentrations of the contraceptive combined with ethinylestradiol and levonorgestrel were prepared (C1-0.78/ 3.9 mcg/mL; C2-1.56/ 7.8 mcg/mL and C3-3.12/15.6 mcg/mL) and three concentrations of contraceptive combined with ethinylestradiol and desogestrel (C1-0.78/ 3.9mcg/mL; C2-1.56/ 7.8 mcg/mL and C3-3.12/15.6 mcg/mL), all of which tested isolated from each other. For negative control, Tween 80 (1%) was used, and for positive control, doxorubicin (0.4 mM). Results: The carcinogenic effect was observed only at the highest concentration of the combined contraceptive of ethylniestradiol with desogestrel (C3). All combined contraceptive concentrations of ethinylestradiol and levonorgestrel (C1, C2 and C3) and the lowest concentrations of ethinylestradiol and desogestrel (C1 and C2) had tumor frequencies that did not differ significantly from the negative control. Conclusion: It was concluded that third-generation oral contraceptives showed carcinogenic potential in D. melanogaster, but only at higher concentrations.
References
A, A., & El-din, A. E. (2018). Genotoxic and carcinogenic studies of norgestrel in Drosophila Melanogaster. Asian Journal of Pharmaceutical and Clinical Research, 11(10), 372. https://doi.org/10.22159/ajpcr.2018.v11i10.27374
Andrade, V. S. M. de, Morais, M. C., Mangueira, C. D. M., & Silveira, S. J. S. da. (2023). A relação entre o uso de anticoncepcionais e o desenvolvimento do câncer de mama. Facit Business and Technology Journal, 2(47). https://jnt1.websiteseguro.com/index.php/JNT/article/view/2668/1816
Brandt, G., Rodrigues De Oliveira, A., & Burci, L. (2018). Anticoncepcionais hormonais na atualidade: um novo paradigma para o planejamento familiar. Revista Gestão e Saúde. https://www.herrero.com.br/files/revista/fileffb43b6252282b433e193bacf91d43f7.pdf
Brito, M. B., Nobre, F., & Vieira, C. S. (2011). Contracepção hormonal e sistema cardiovascular. Arquivos Brasileiros de Cardiologia, 96(4), 81–89. https://doi.org/10.1590/s0066-782x2011005000022.
Bonan, C., Teixeira, L. A., & Nakano, A. R. (2017). Absorção e metabolização dos hormônios sexuais e sua transformação em tecnologias contraceptivas: percursos do pensamento médico no Brasil. Ciência & Saúde Coletiva, 22(1), 107–116. https://doi.org/10.1590/1413-81232017221.26532016
Callegari, L. S., Darney, B. G., Godfrey, E. M., Sementi, O., Dunsmoor-Su, R., & Prager, S. W. (2014). Evidence-based selection of candidates for the levonorgestrel intrauterine device (IUD). Journal of the American Board of Family Medicine: JABFM, 27(1), 26–33. https://doi.org/10.3122/jabfm.2014.01.130142
Candido, C. D.; Carlos, I. Z. & Peccinini, R. G. (2013) Avaliação de Distribuição de doxorrubicina incorporada em microemulsão lipídica em tecido tumoral e cardíaco em Camundongos. (Dissertação- Programa de Pós-graduação em Ciências Farmacêuticas). Universidade Estadual Paulista Júlio de Mesquita Filho, Araraquara, São Paulo, Brasil.
Ciclo 21®️: Levonorgestrel 0,15mg + Etinilestradiol 0,03 mg. (2014) Bula de Remédio. Farmacêutica Responsável: Florentino de Jesus Krencas. Embu-Guaçu, União Química Farmacêutica Nacional S/A.
D’Amato, C. C. (2018). Avaliação do potencial carcinogênico da associação dos hormônios etinilestradiol e levonorgestrel por meio do teste para detecção de tumor epitelial em Drosophila melanogaster. (Trabalho de Conclusão de Curso Graduação em Ciências Biológicas), Universidade Federal de Uberlândia, Minas Gerais, Brasil. https://repositorio.ufu.br/handle/123456789/23414
Dragoman, M. V. (2014). The combined oral contraceptive pill-recent developments, risks and benefits. Best Practice & Research Clinical Obstetrics & Gynaecology, 28(6), 825–834. https://doi.org/10.1016/j.bpobgyn.2014.06.003
Düsman, E., Berti, A. P., Soares, L. C., & Vicentini, V. E. P. (2012). Principais agentes mutagênicos e carcinogênicos de exposição humana. Revista de Saúde e Biologia, 7(2). https://revista2.grupointegrado.br/revista/index.php/sabios/article/view/943
Fauldoxo®: cloridrato de doxorrubicina.(2017) Bula de Remédio. Farmacêutica Responsável: Cintia Delphino de Andrade. São Paulo, Libbs Farmacêutica Ltda.
Finotti, M. (2015) Manual de Anticoncepção da Febrasgo. São Paulo.
Joosten HF, van Acker FA, van den Dobbelsteen DJ, Horbach GJ & Krajnc El. (2004) Genotoxicity of hormonal steroids. Toxicology Letters. 151(1). 113-34. 10.1016/j.toxlet.2004.01.018.
Kumar, V., Abbas, A., Fausto & N. J. Aster (2010). Patologia: bases patológicas das doenças (8a ed). Elsevier.
Schindler, A. E. (2012). Non-contraceptive benefits of oral hormonal contraceptives. International Journal of Endocrinology and Metabolism, 11(1). https://doi.org/10.5812/ijem.4158
Mitre, E. I., Figueira, A. S., Rocha, A. B., & Alves, S. M. C. (2006). Avaliações audiométrica e vestibular em mulheres que utilizam o método contraceptivo hormonal oral. Revista Brasileira de Otorrinolaringologia, 72, 350–354. https://doi.org/10.1590/S0034-72992006000300009
Miyazaki, T., Sueoka, K., Dharmarajan, A. M., Atlas, S. J., Bulkley, G. B., & Wallach, E. E. (1991). Effect of inhibition of oxygen free radical on ovulation and progesterone production by the in-vitro perfused rabbit ovary. Journal of Reproduction and Fertility, 91(1), 207–212. https://doi.org/10.1530/jrf.0.0910207
Nussbaum, R. L., Mcinnes, R. R., Willard, H. F., Hamosh, A., Thompson, J. S., & Thompson, M. W. (2016). Thompson & Thompson genetics in medicine. (8th ed.). Elsevier/Saunders.
Oliveira, M. V. O., Lima, A. P. S. B., Conforti, D. B., Bittencourt, L. K., Oliveira, M. R. M, & Angelo, V. T. (2015) Benefícios não contraceptivos do sistema intrauterino liberador de levonorgestrel na endometriose. Revista UNILUS Ensino e Pesquisa, Santos, 12 (27).
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. UFSM.
Primera®️: Desogestrel 150 mcg + Etinilestradiol 30 mcg. (2019). Bula do Remédio. Farmacêutica Responsável: Dra. Ivanete A. Dias Assi. São Paulo, Eurofarma Laboratórios S.A.
Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy. Journal of Cancer Research and Therapeutics, 10(4), 853–858. https://doi.org/10.4103/0973-1482.139267
Scala, C., Maggiore, U., Valentino Remorgida, Pier Luigi Venturini, & Ferrero, S. (2013). Drug safety evaluation of desogestrel. Expert Opinion on Drug Safety 12(3), 433–444. https://doi.org/10.1517/14740338.2013.788147
Shchelkunova, T. A., & Morozov, I. A. (2016). Progestins and carcinogenesis. Molecular Biology 50(1), 10–26. https://doi.org/10.7868/S0026898416010171
Estrêla Da Silva, A., Serakides, R., Dantas Cassali, G., & Veterinário, M. (2004). Carcinogênese hormonal e neoplasias hormônio-dependentes Hormonal carcinogenesis and hormone dependents neoplasm. Ciência Rural, 34(2), 625–633.
Silva, M. R. & Oliveira R. G. S. (2017). Avaliação do efeito carcinogênico e anticarcinogênico do levonorgestrel através do teste de detecção de clones de tumores epiteliais em células somáticas de Drosophila melanogaster. Revista Perquirere. 14(1) 200-217.
Soini, T., Hurskainen, R., Grénman, S., Mäenpää, J., Paavonen, J., & Pukkala, E. (2014). Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland. Obstetrics & Gynecology, 124(2), 292–299. https://doi.org/10.1097/aog.0000000000000356
Vasconcelos, M. A., Orsolin, P. C., Silva-Oliveira, R. G., Nepomuceno, J. C., & Spanó, M. A. (2017). Assessment of the carcinogenic potential of high intense-sweeteners through the test for detection of epithelial tumor clones (warts) in Drosophila melanogaster. Food and Chemical Toxicology, 101, 1–7. https://doi.org/10.1016/j.fct.2016.12.028
Van Hylckama Vlieg, A., Helmerhorst, F. M., Vandenbroucke, J. P., Doggen, C. J. M., & Rosendaal, F. R. (2009). The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ, 339(aug13 2), 2921–2921. https://doi.org/10.1136/bmj.b2921
WHO, World Health Organization. (2000). The World Health Report. Health Systems: Improving Performance. Geneva.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Giovana Vilela Rocha; Adriano Pereira Daniel; Priscila Capelari Orsolin; Flávio Rocha Gil
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
